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Background
In developed countries, the morbidity and mortality in Human 
Immunodeficiency Virus (HIV) patients is significantly induced by 
chronic Hepatitis C Virus (HCV) co-infection. It is estimated to have 
about one-third of HIV patients co-infected with HCV. These patients 
usually require immediate HCV treatment as they tolerate poorly 
towards antiretroviral treatment, progress more rapidly to end-stage 
liver disease and often lead to death [1,2]. 
For decades, the standard therapy for HCV infection relies on the 
combination of pegylated interferon and ribavirin (PEG-IFN/RBV). 
This treatment is known to be less effective towards HIV/HCV co-
infected patients, with a lower rate of Sustained Virological Response 
(SVR) and a higher rate of viral relapse upon treatment completion 
[3,4]. Recent studies identified two Single Nucleotide Polymorphisms 
(SNPs) rs12979860 and rs8099917 that located near interleukin-28B 
(IL-28B) and acted as important baseline predictors for PEG-IFN/RBV 
treatment responses. Strong association between favourable genotypes 
(C/C for rs12979860 and T/T for rs8099917) and high rate of SVR were 
observed in several genome wide association studies [5-8]. 
Clinical management on HIV/HCV co-infected patients is always 
more complicated than mono-infected patients. Several commercial 
assays and sequencing are the major IL-28B polymorphisms detection 
methods, yet they are relatively expensive and time-consuming. This 
study aimed to develop a rapid and cost-effective duplex HybProbe 
real-time assay to detect both rs12979860 and rs8099917 SNPs in a 
single reaction and estimate the prevalence of IL-28B, HIV-1 and HCV 
subtypes among co-infected patients in this locality. 
Objectives
To evaluate the performance of a newly developed HybProbe 
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Abstract
 Conventional treatment for chronic HCV infection relies on the combination of peg-interferon and ribavirin 
therapy. Both interleukin-28B (IL-28B) polymorphisms and HCV genotypes serve as the strongest predictive values 
for therapeutic prognosis. The treatment regimens for HIV/HCV co-infected patients are more complex and dependent 
on various host immune and viral factors. A rapid and cost-effective IL-28B genotyping tool is therefore crucial to 
assist clinicians on better patient management. This study aimed to evaluate the performance of a newly developed 
HybProbe duplex real-time PCR assay in detecting IL-28B polymorphisms on rs12979860 and rs8099917, and 
to estimate the prevalence of IL-28B polymorphisms among HIV/HCV co-infected patients in Hong Kong. A total 
of 88 HIV/HCV co-infected patients were recruited at the Integrated Treatment Centre during 2009 to 2014. IL-
28B polymorphisms on rs12979860 and rs8099917 were determined by an in-house HybProbe assay with melting 
curve analysis. For assay evaluation, IL-28B polymorphisms of 46 samples with diverse HIV/HCV genotypes were 
confirmed by Sanger sequencing. Both in-house HybProbe assay and sequencing results for IL28B polymorphisms 
determination were completely concordant. Among the 88 HIV/HCV co-infected, the frequency of rs12979860 wild-
type (C/C) was 88.6%, heterozygous mutant (C/T) was 9.1% and remaining 2.3% homozygous mutant (T/T). The 
prevalence of IL-28B polymorphisms in rs8099917 was slightly differed, which had 90.9% wild-type (T/T), 6.8% 
heterozygous mutant (G/T) and 2.3% homozygous mutant (G/G). This novel duplex assay could allow clinicians to 
make early decision on treatment option for HIV/HCV co-infected patients by detecting rs12979860 and rs8099917 
polymorphisms simultaneously.
Utilization of a Duplex HybProbe Real-Time PCR to Detect and Estimate 
IL-28B Polymorphisms Prevalence among HIV/HCV Co-infected Patients 
in Hong Kong
Sabrina Wai-Chi To1, Gilman Kit-Hang Siu2, Ka-Hing Wong3, Kenny Chi-Wai Chan3, King-Tai Yuen1, Hon-Man Ng1 and Wing-Cheong Yam1*
1Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Hong Kong, Special Administrative Region, China
2Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong, Special Administrative Region, China
3 Integrated Treatment Centre, Special Preventive Programme, Centre of Health Protection, Department of Health, Hong Kong, Special Administrative Region, China
duplex real-time PCR assay in detecting IL-28B polymorphisms on 
rs12979860 and rs8099917, and to estimate the prevalence of IL-28B 
polymorphisms among HIV/HCV co-infected patients in Hong Kong. 
Study Design
A total of 88 HIV/HCV co-infected patients were recruited at the 
Hong Kong Government Integrated Treatment Centre during 2009 to 
2014. Whole blood samples were collected after patient consent. The 
IL-28B polymorphisms on rs12979860 and rs8099917 of all samples 
were detected by the HybProbe assay with melting curve analysis. 
The duplex PCR assay was amplified by LightCycler® FastStart DNA 
Master HybProbe (Roche Diagnostics, Germany), with two pairs of 
primers and hybridization probes specifically targeting rs12979860 and 
rs8099917 (Table 1). For assay evaluation, IL-28B polymorphisms of 
46 samples were further confirmed by Sanger sequencing. HCV viral 
load was quantitated by Abbott m2000 RealTime HCV assay (Abbott 
Laboratories, USA) while HIV-1 and HCV genotypes were confirmed 
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by our in-house methods [9,10]. Statistical analysis was performed by 
Graphpad Prism version 6(Graphpad software, California, US).
Results
Basic demographic characteristics of HIV/HCV co-infected 
patients in this study are presented in Table 2. There were 82 males 
(93.2%) included in this study, with an overall median age at 39 (range 
21 – 63 years). Nearly 65% of the study population were Chinese 
with approximately 33% non-Chinese Asians. The in-house HIV-1 
genotyping analysis revealed that the patients were infected by subtype 
B (20.5%), CRF01_AE (47.7%) and C or BC recombinants (15.9%). 
HCV genotypes were detected in 71 patients, including genotype 
1/1a/1b (30.7%), 3a/3b (26.1%) and 6a/6d/6e (23.9%). Due to low HIV-1 
or HCV viral load at sample collection, about 15 – 20% of the co-infected 
patients were unable to have either or both viral genotyping results. 
The HybProbe assay performance was evaluated among 46 co-
infected samples, using Sanger sequencing as gold standard. Diverse 
HIV-1 subtypes (5 subtype B, 3 subtype C, 29 CRF01_AE, 4 CRF07_BC, 
1 CRF08_BC and 4 undetermined) and HCV genotypes (2 genotype 1, 9 
genotype 1a, 6 genotype 1b, 2 genotype 3a, 1 genotype 3b, 9 genotype 6a, 1 
genotype 6d, 3 genotype 6e and 13 undetermined) samples were included 
for evaluation. Sanger sequencing required two individual reactions 
and manual sequence proof-reading whereas in-house HybProbe assay 
required melting curve analysis to interpret the SNPs on rs12979860 and 
rs8099917. Rs12979860 C/C wild-type had a melting peak at 64℃ ± 1℃ 
while T/T mutant had a lower melting temperature at 54℃ ± 1℃ (Figure 
1A). For rs8099917, T/T wild-type melted at 64℃ ± 1℃ whereas mutant 
G/G melted at 57℃ ± 1℃ (Figure 1B). Heterozygous mutants (C/T of 
rs12979860 and T/G of rs8099917) could be typically interpreted when 
both melting peaks of wild-type and mutant were seen. Both systems 
rs12979860
Forward Primer 5’- GCGCTTATCGCATACGGCTA - 3’
Reverse Primer 5’- TCACAGAAGGGAGCCCTGCC - 3’
Sensor Probe 5’- CGAAGGCGCGAACCAGG-Fluorescein - 3’
Anchor Probe 5’- LC Red 640 - TGAATTGCTCCGCGCTCCC-Phosphate - 3’
rs8099917
Forward Primer 5’- AAGTAACACTTGTTCCTTGTAAAAGATTCC - 3’
Reverse Primer 5’- CGCTATAATTAAAGATGTGGGAGAATGCAA - 3’
Sensor Probe 5’ - CCTTTCTGTGAGCAATTTCACCCAA- Fluorescein - 3’
Anchor Probe 5’ - LC Red 705 - TGGAACCATGCTGTATACAGTTTGGTAGC-Phosphate – 3’
C or T indicates SNPs position.
Table 1:  Primers and probes for IL-28B Genotyping assays.
Total rs12979860 P-value* rs8099917 P-value*
n (%) CC CT/TT TT TG/GG
(n=78) (n=10) (n=80) (n=8)
Gender 0.5260 0.4455
Male 82 (93.2) 73 (83.0) 9 (10.2) 75 (85.2) 7 (8.0)
Female 6 (6.8) 5 (5.7) 1 (1.1) 5 (5.7) 1 (1.1)
Ethnicity 0.7117 0.2572
Chinese 57 (64.8) 50 (56.8) 7 (8.0) 50 (56.8) 7 (8.0)
Asian 29 (33.0) 27 (30.7) 2 (2.3) 28 (31.8) 1 (1.1)
Undetermined 2 (2.3) 1 (1.1) 1 (1.1) 1 (1.1) 1 (1.1)
Risk of Infection N/A N/A
IDU 18 (20.5) 17 (19.3) 1 (1.1) 17 (19.3) 1 (1.1)
Homosexual 7 (8.0) 7 (8.0) -- 7 (8.0) --
Heterosexual 2 (2.3) 2 (2.3) -- 2 (2.3) --
Undetermined 61 (69.3) 52 (59.0) 9 (10.2) 54 (61.4) 7 (8.0)
HIV-1 subtypes 0.0662 0.1006
B 18 (20.5) 13 (14.8) 5 (5.7) 14 (15.9) 4 (4.5)
CRF01_AE 42 (47.7) 39 (44.3) 3 (3.4) 40 (45.5) 2 (2.3)
C or CRF07_BC or
CRF08_BC 14 (15.9) 13 (14.8) 1 (1.1) 13 (14.8) 1 (1.1)
PCR -ve 14 (15.9) 13 (14.8) 1 (1.1) 13 (14.8) 1 (1.1)
HCV genotypes 0.1267 N/A
1 / 1a / 1b 27 (30.7) 26 (29.5) 1 (1.1) 27 (30.7) --
3a / 3b 23 (26.1) 18 (20.5) 5 (5.7) 18 (20.5) 3 (3.4)
6a / 6d / 6e 21 (23.9) 19 (21.6) 2 (2.3) 20 (22.7) 1 (1.1)
PCR -ve 17 (19.3) 15 (17.0) 2 (2.3) 15 (17.0) 2 (1.1)
N/A: Not available; -ve: negative; IDU: Intravenous drug users
*Statistics: Fisher’s exact tests
Table 2:  Basic demographic characteristics of HIV/HCV co-infected patients.
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Figure 1:  Melting curves and melting peaks analysis of rs12979860 (Figure 1A) and rs8099917 (Figure 1B) single nucleotide polymorphisms detection by in-house 
HybProbe assay. Heterozygous mutants could be interpreted when both melting peaks or wild-type and mutant were seen.
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concordantly detected two C/T and one T/T mutants of rs12979860, as 
well as one G/T and one G/G mutants of rs8099917. 
Among the 88 HIV/HCV co-infected patients in this locality, 
the frequency of rs12979860 wild-type (C/C) was 88.6%, while the 
frequency of C/T and T/T mutants was 9.1% and 2.3% respectively. The 
prevalence of IL-28B polymorphisms is rs8099917 was significantly 
differed (P < 0.0001, Fisher's exact tests), which had 90.9% wild-
type (T/T), 6.8% G/T and 2.3% G/G mutants. This study revealed no 
association between HIV-1 subtypes, HCV genotypes, ethnicities or 
gender between rs12979860 or rs8099917 unfavourable genotypes. 
Most of the patients had concordant wild-type or mutant genotypes 
between both rs12979860 and rs8099917. Exceptions were seen in 
one Asian and one patient with undetermined ethnicity as they had 
unfavourable C/T on rs12979860 but favourable wild-type T/T on 
rs8099917. 
Discussion
The identification of both rs12979860 and rs8099917 
favourable genotypes largely enhanced the rate of SVR in HIV/
HCV co-infected patients. To our knowledge, this is the first in-
house duplex IL-28B real-time HybProbe assay that successfully 
identifies both rs12979860 and rs8099917 SNPs simultaneously in 
one single tube. The HybProbe assay used LC-RED640 and LC-
RED705 acceptor dyes to detect both SNPs in a single run instead 
of individual sequencing reactions. The melting temperatures for 
both SNPs interpretation were also very distinct, which was 10℃ for 
rs12979860 and 6℃ for rs8099917, respectively. Traditional Sanger 
sequencing consists of several tedious experimental steps, including 
end-point PCR and capillary analysis, whereas the in-house duplex 
assay largely shortened the turnaround time from two days to two 
hours with at least 50% of running cost reduction. 
The in-house HybProbe assay achieved 100% concordant 
SNPs interpretation with the sequencing results. Both Chinese and 
Asians were included in this study, together with diverse HIV-1 and 
HCV genotypes, suggesting that the current assay would be largely 
applicable to global laboratories. Both HIV-1 subtype B and CRF01_
AE accounted for about 80% of local infections in Hong Kong [11]. A 
higher prevalence of CRF01_AE (47.7%) was noticed in our patients, 
whereas the prevalence for subtype B was relatively low (20.5%). 
Limited information on routes of infection was available at the time 
of study, though about a-fifth of the study population were infected 
via intravenous drug use. Conversely the prevalence of HCV genotype 
1, 3 and 6 were roughly similar, which was inconsistent with previous 
local studies, suggesting that the HIV/HCV co-infection might pre-
dominantly affect intravenous drug users with distinct epidemiological 
and transmission pattern. [10,12].
Clinical management among HIV/HCV co-infected patients 
usually induced more complications due to drug-drug interaction and 
patients’ immune status. Poor SVR rate was mainly associated with 
HCV genotype 1 and unfavourable IL-28B SNPs yet the information 
on other HCV genotypes and HIV co-infection was scarce. Two of 
our patients had C/T mutant on rs12979860 but wild-type T/T on 
rs8099917. Their treatment response towards 48-week of PEG-IFN/
RBV should be analysed in greater details to assess the impact of 
discordant IL-28B polymorphisms. Due to data availability, the HIV/
HCV treatment history and rate of SVR were insufficient for further 
investigation on the relationship between IL28B polymorphisms, 
HIV/HCV genotypes and treatment responses among HIV/HCV co-
infected patients. 
Conclusion
This study developed a simple and efficient IL28B duplex real-
time HybProbe assay with excellent performance on rs12979860 
and rs8099917 SNPs detection. The rapid detection allows clinicians 
to make early decision on treatment option and duration. Both C/C 
and T/T wild-types of rs12979860 and rs8099917 were prevalent in 
our locality. No significant association were observed between IL28B 
polymorphisms and HIV/HCV genotypes. 
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